Pharmacoeconomic Analysis of Antidepressants for Major Depressive Disorder in the United Kingdom

被引：0
|
作者：
Hugh Freeman
Steve Arikian
Alan Lenox-Smith
机构：
[1] Green College,Medical Department
[2] The Analytica Group,undefined
[3] Wyeth Laboratories,undefined
来源：
PharmacoEconomics | 2000年 / 18卷
关键词：
Major Depressive Disorder; Dropout Rate; Venlafaxine; Major Depressive Disorder; Pharmacoeconomic Analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To estimate the cost effectiveness of different classes of antidepressants in the UK National Health Service.
引用
收藏
页码：143 / 148
页数：5
相关论文
共 50 条
  • [1] Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom
    Freeman, H
    Arikian, S
    Lenox-Smith, A
    PHARMACOECONOMICS, 2000, 18 (02) : 143 - 148
  • [2] A pharmacoeconomic comparison of escitalopram and duloxetine in treatment of major depressive disorder (MDD) in the United Kingdom
    Wade, A. G.
    Fernandez, J. L.
    Francois, C.
    Hansen, K.
    Despiegel, N.
    Danchenko, N.
    VALUE IN HEALTH, 2007, 10 (06) : A306 - A306
  • [3] C-QUALITY: A COST AND QUALITY OF LIFE PHARMACOECONOMIC ANALYSIS OF ANTIDEPRESSANTS IN MAJOR DEPRESSIVE DISORDER IN ITALY
    Katz, P.
    Heiman, F.
    Ripellino, C.
    VALUE IN HEALTH, 2013, 16 (07) : A549 - A549
  • [4] Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder
    Einarson, TR
    Addis, A
    Iskedjian, M
    PHARMACOECONOMICS, 1997, 12 (02) : 286 - 296
  • [5] C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy
    Mencacci, Claudio
    Aguglia, Eugenio
    Biggio, Giovanni
    Cappellari, Lodovico
    Di Sciascio, Guido
    Fagiolini, Andrea
    Maina, Giuseppe
    Tortorella, Alfonso
    Katz, Pablo
    Ripellino, Claudio
    ADVANCES IN THERAPY, 2013, 30 (07) : 697 - 712
  • [6] C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy
    Claudio Mencacci
    Eugenio Aguglia
    Giovanni Biggio
    Lodovico Cappellari
    Guido Di Sciascio
    Andrea Fagiolini
    Giuseppe Maina
    Alfonso Tortorella
    Pablo Katz
    Claudio Ripellino
    Advances in Therapy, 2013, 30 : 697 - 712
  • [7] PHARMACOECONOMIC ANALYSIS OF AGOMELATINE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN KAZAKHSTAN
    Adilgozhina, G.
    Abdukhakimova, D.
    Zhumagali, Y.
    Bektur, C.
    Kostuyk, A.
    Nurgozhin, T.
    VALUE IN HEALTH, 2017, 20 (05) : A297 - A297
  • [8] Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom
    Young, A. H.
    Evitt, L.
    Brignone, M.
    Diamand, F.
    Atsou, K.
    Campbell, R.
    Cure, S.
    Danchenko, N.
    JOURNAL OF AFFECTIVE DISORDERS, 2017, 218 : 291 - 298
  • [9] Major depressive disorder, antidepressants, and sexual dysfunction
    Clayton, Anita H.
    Montejo, Angel L.
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 : 33 - 37
  • [10] Emerging antidepressants to treat major depressive disorder
    Block, Samantha G.
    Nemeroff, Charles B.
    ASIAN JOURNAL OF PSYCHIATRY, 2014, 12 : 7 - 16
12345